Therapeutic Hypothermia for Cardiac Arrest
(ICECAP Trial)
Trial Summary
What is the purpose of this trial?
A multicenter, randomized, adaptive allocation clinical trial to determine if increasing durations of induced hypothermia are associated with an increasing rate of good neurological outcomes and to identify the optimal duration of induced hypothermia for neuroprotection in comatose survivors of cardiac arrest.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Therapeutic Hypothermia for Cardiac Arrest?
Therapeutic hypothermia has been shown to improve survival and neurological outcomes in patients who survive cardiac arrest. Studies indicate that faster cooling leads to better outcomes, and implementing a targeted temperature protocol can help achieve this. Additionally, therapeutic hypothermia is part of current guidelines for post-resuscitation care, highlighting its importance in improving patient recovery.12345
Is therapeutic hypothermia generally safe for humans?
Therapeutic hypothermia can have side effects, including issues with the heart, fluid balance, and infections, and it requires careful monitoring and management. These side effects are seen in various conditions, including cardiac arrest and severe brain injury, and more research is needed to fully understand and manage these risks.678910
How is the treatment Therapeutic Hypothermia unique for cardiac arrest?
Therapeutic Hypothermia is unique because it involves cooling the body to a target temperature of 32-34°C to improve survival and brain function after cardiac arrest, unlike other treatments that do not focus on temperature management. It is one of the few advancements that has shown to improve outcomes in cardiac arrest patients, especially when started early after resuscitation.12111213
Research Team
William Meurer
Principal Investigator
University of Michigan
Robert Silbergleit
Principal Investigator
University of Michigan
Romer Geocadin
Principal Investigator
Johns Hopkins University
Eligibility Criteria
This trial is for adults who've been in a coma after being resuscitated from a cardiac arrest outside of the hospital. They must be cooled to below 34 degrees Celsius within 4 hours of the event, with plans to maintain life support for at least 96 hours. It's not for those unstable after resuscitation, with pre-existing severe neurological issues or terminal illnesses, planned early life support withdrawal, sepsis-related arrests, or prisoners.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive varying durations of induced hypothermia to determine optimal neuroprotection
Rewarming
Controlled rewarming to a temperature of 36.5°C over a period equal to the cooling duration
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Therapeutic Hypothermia
Therapeutic Hypothermia is already approved in United States, European Union, Canada for the following indications:
- Cardiac arrest in adults and children
- Birth asphyxia in newborns
- Cardiac arrest in adults and children
- Birth asphyxia in newborns
- Cardiac arrest in adults and children
- Birth asphyxia in newborns
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Michigan
Lead Sponsor
National Institutes of Health (NIH)
Collaborator
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborator
Medical University of South Carolina
Collaborator
Johns Hopkins University
Collaborator